AU Stock MarketDetailed Quotes

TYP Tryptamine Therapeutics Ltd

Watchlist
  • 0.038
  • +0.001+2.70%
20min DelayMarket Closed Dec 24 12:09 AET
48.50MMarket Cap-0.42P/E (Static)

About Tryptamine Therapeutics Ltd Company

Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Company Profile

SymbolTYP
Company NameTryptamine Therapeutics Ltd
Founded2013
MarketASX
Employees50
Fiscal Year Ends06-30
AddressC/o Bio101 Financial Advisory Pty Ltd 697 Burke Road, Suite 201
CityMelbourne
CountryAustralia
Zip Code3124
Phone+61 390920475
Websitehttps://www.tryptherapeutics.com
Share RegistryAUTOMIC REGISTRY SERVICES Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000 02 9698 5414

Company Executives

  • Name
  • Position
  • Salary
  • Peter Molloy
  • Chief Business Officer and Executive Director,Non-Executive Director
  • --
  • Mark Davies
  • Non-Executive Chairman,Non-Executive Director
  • --
  • Jason Carroll
  • Non-Executive Director
  • --
  • Gage Jull
  • Non-Executive Director
  • --
  • Clarke Barlow
  • Non-Executive Director
  • --
  • Christopher Ntoumenopoulos
  • Non-Executive Director
  • --
Trending AU Stocks
ASX High Dividend ASX High Dividend
Symbol Mini Chart % Chg
Woodside Energy Group Ltd
WDS
+0.92%
Origin Energy Ltd
ORG
+0.74%
National Australia Bank Ltd
NAB
+0.67%
Telstra Group Ltd
TLS
+0.50%
ANZ Group Holdings Ltd
ANZ
+0.49%

Unlock the Full List